IRLAB Therapeutics: IRLAB Nominates New Candidate Drug, IRL757, to Treat Apathy in Neurological Disorders
GOTHENBURG, SWEDEN / ACCESSWIRE / March 21, 2022 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)IRLAB (Nasdaq Stockholm: IRLAB A) takes important steps expanding the development pipeline and nominates a